Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
Date:3/4/2013

CHESTERBROOK, Pa., March 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Cowen and Company 33rd Annual Global Healthcare Conference to be held March 4-6, 2013 at the Marriott Copley Place in Boston. Mr. Adrian Adams , Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 11:20 a.m. ET on Wednesday, March 6, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on March 6, 2013. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for ninety days after the event.   

About Auxilium
Auxilium is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S.  GlaxoSmithKline LLC co- promotes Testim with Auxilium in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA on November 6, 2012 and has been accepted for standard review with a PDUFA date of September 6, 2013. Additionally, collagenase clostridium histolyticum ("CCH") is in phase II of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase II of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium is also developing a high concentration testosterone gel product. Auxilium also has rights to pursue additional indications for CCH.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the "SEC") on February 26, 2013. While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so. Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

For More Information, Contact:

Contacts:
James E. Fickenscher /CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
jfickenscher@auxilium.com

William Q. Sargent Jr. / VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
2. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
4. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
6. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
7. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
10. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
11. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Nov. 29, 2016 Several leading ... by Accera, Inc. at 11 a.m. EST ... International Conference on Clinical Trials for Alzheimer,s Disease (CTAD). ... metabolism in Alzheimer,s disease and therapeutic targets that address ... "Following the recent failure of another therapy targeting ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets ... Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End ... Forecasts to 2021" report to their offering. ... , , ... Million in 2021 from USD 574.8 Million in 2016, growing at ...
(Date:12/5/2016)... December 5, 2016 According to a new report published ... Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the global ... reach $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 ... four-fifths share. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... The new ... the individual looking to buy neoprene knee sleeves for lifting and any ... design focuses heavily on two main aspects to provide a higher quality knee sleeve ...
(Date:12/5/2016)... Wallingford, CT (PRWEB) , ... December 05, 2016 ... ... hemostatic devices, announces today that they have teamed up with The American College ... Working with the ACS’s Committee on Trauma, the “Bleeding Control Basic” course is ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... transitions and many more tools allowing FCPX editors to create professional looking video ... Studios. , Perfect Harmony contains a beautifully designed 3D environment for placing ...
(Date:12/4/2016)... Viejo, California (PRWEB) , ... December 04, 2016 ... ... lower third presets that have new attractive animation styles with unique displacement design ... Displace features 30 pre-animated lower third designs. Choose from a variety of design ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
Breaking Medicine News(10 mins):